A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed[1]dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma.
Principal Investigator: Micaela Hernberg
HUS Helsinki University Hospital, Comprehensive Cancer Center
